Regulation of mprF in daptomycin-nonsusceptible Staphylococcus aureus strains

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 6, 2009, Pages 2636-2637

  Yang, Soo Jin ^a,g   Xiong, Yan Q ^a,b,c   Dunman, Paul M ^d   Schrenzel, Jacques ^e   François, Patrice ^e   Peschel, Andreas ^f   Bayer, Arnold S ^a,b,c  

^a LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^e UNIVERSITY HOSPITAL   (Switzerland)

^f UNIVERSITY OF TÜBINGEN   (Germany)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DAPTOMYCIN; DIGOXIGENIN; PHOSPHATIDYLGLYCEROL;

AMINO ACID SEQUENCE; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL ENDOCARDITIS; BACTERIAL GENE; BACTERIAL OUTER MEMBRANE; BACTERIAL VIRULENCE; GENE CONTROL; GENE MUTATION; GENE OVEREXPRESSION; MPRF GENE; NONHUMAN; OPEN READING FRAME; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; STAPHYLOCOCCUS AUREUS; STRAIN DIFFERENCE;

AMINOACYLTRANSFERASES; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; DAPTOMYCIN; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; STAPHYLOCOCCUS AUREUS;

EID: 67049086887     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01415-08     Document Type: Article

References (17)

1. Friedman, L., J. D. Alder, and J. A. Silverman. 2006. Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus. Antimicrob. Agents Chemother. 50:2137-2145.
2. Hayden, M. K., K. Rezai, R. A. Hayes, K. Lolans, J. P. Quinn, and R. A. Weinstein. 2005. Development of daptomycin resistance in vivo in methicillin- resistant Staphylococcus aureus. J. Clin. Microbiol. 43:5285-5287.
3. Jones, T., M. R. Yeaman, G. Sakoulas, S.-J. Yang, R. A. Proctor, H.-G. Sahl, J. Schrenzel, Y. Q. Xiong, and A. S. Bayer. 2008. Failures in clinical treatment of Staphylococcus aureus infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding. Antimicrob. Agents Chemother. 52:269-278.
4. Julian, K., K. Kosowska-Shick, C. Whitener, M. Roos, H. Labischinski, A. Rubio, L. Parent, L. Ednie, L. Koeth, T. Bogdanovich, and P. C. Appelbaum. 2007. Characterization of a daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus strain in a patient with endocarditis. Antimicrob. Agents Chemother. 51:3445-3448.
5. Li, M., D. J. Cha, Y. Lai, A. E. Villaruz, D. E. Sturdevant, and M. Otto. 2007. The antimicrobial peptide-sensing system aps of Staphylococcus aureus. Mol. Microbiol. 66:1136-1147.
6. Peschel, A. 2002. How do bacteria resist human antimicrobial peptides? Trends Microbiol. 10:179.
7. Peschel, A., R. W. Jack, M. Otto, L. V. Collins, P. Staubitz, G. Nicholson, H. Kalbacher, W. F. Nieuwenhuizen, G. Jung, A. Tarkowski, K. P. M. van Kessel, and J. A. G. van Strijp. 2001. Staphylococcus aureus resistance to human defensins and evasion of neutrophil killing via the novel virulence factor MprF is based on modification of membrane lipids with L-lysine. J. Exp. Med. 193:1067-1076.
8. Peschel, A., and L. Vincent Collins. 2001. Staphylococcal resistance to antimicrobial peptides of mammalian and bacterial origin. Peptides 22:1651. (Pubitemid 32918244)
9. Pillai, S. K., H. S. Gold, G. Sakoulas, C. Wennersten, R. C. Moellering, Jr., and G. M. Eliopoulos. 2007. Daptomycin nonsusceptibility in Staphylococcus aureus with reduced vancomycin susceptibility is independent of alterations in MprF. Antimicrob. Agents Chemother. 51:2223-2225.
10. Sakoulas, G., W. Rose, M. J. Rybak, S. Pillai, J. Alder, R. C. Moellering, Jr., and G. M. Eliopoulos. 2008. Evaluation of endocarditis caused by methicillin- susceptible Staphylococcus aureus developing nonsusceptibility to daptomycin. J. Clin. Microbiol. 46:220-224.
11. Skiest, D. J. 2006. Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin. J. Clin. Microbiol. 44:655-656.
12. Weidenmaier, C., A. Peschel, V. A. J. Kempf, N. Lucindo, M. R. Yeaman, and A. S. Bayer. 2005. DltABCD- and MprF-mediated cell envelope modifications of Staphylococcus aureus confer resistance to platelet microbicidal proteins and contribute to virulence in a rabbit endocarditis model. Infect. Immun. 73:8033-8038.
13. Weidenmaier, C., A. Peschel, Y.-Q. Xiong, S. A. Kristian, K. Dietz, M. R. Yeaman, and A. S. Bayer. 2005. Lack of wall teichoic acids in Staphylococcus aureus leads to reduced interactions with endothelial cells and to attenuated virulence in a rabbit model of endocarditis. J. Infect. Dis. 191:1771-1777.
14. Xiong, Y.-Q., L. I. Kupferwasser, P. M. Zack, and A. S. Bayer. 1999. Comparative efficacies of liposomal amikacin (MiKasome) plus oxacillin versus conventional amikacin plus oxacillin in experimental endocarditis induced by Staphylococcus aureus: microbiological and echocardiographic analyses. Antimicrob. Agents Chemother. 43:1737-1742.
15. Xiong, Y.-Q., W. VanWamel, C. Nast, M. Yeaman, A. Cheung, and A. Bayer. 2002. Activation and transcriptional interaction between agr RNAII and RNAIII in Staphylococcus aureus in vitro and in an experimental endocarditis model. J. Infect. Dis. 186:668-677.
16. Yang, S.-J., P. M. Dunman, S. J. Projan, and K. W. Bayles. 2006. Characterization of the Staphylococcus aureus CidR regulon: elucidation of a novel role for acetoin metabolism in cell death and lysis. Mol. Microbiol. 60:458-468.
17. Yang, S.-J., K. C. Rice, R. J. Brown, T. G. Patton, L. E. Liou, Y. H. Park, and K. W. Bayles. 2005. A LysR-type regulator, CidR, is required for induction of the Staphylococcus aureus cidABC operon. J. Bacteriol. 187:5893-5900.